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Saudi Arabia, with the enrollment between November
2011 and October 2012. Of 500 patients referred for
elective CARDIAC surgery, 100 (20%) met criteria for
high risk of developing PPCs, of whom were enrolled
and followed up until discharge from hospital after
dividing him to two groups, our new preoperative chest
preparation strategy group (group A) and classic
routinely used group (group B).
Intervention: Patients were randomly assigned to
receive either preoperative strategy (n = 50) or usual care
B strategy (n = 50). Both groups received the postopera-
tive physical therapy.
Main outcome measures: Incidence of PPCs espe-
cially pneumonia, duration of postoperative intubation
and invasive ventilation, Intensive Care Unit (ICU) stay
and hospitalization incidence of requiring re-intubation
and impact of both strategies on postoperative patient
compliance to respiratory therapy.
Results: Both groups were comparable at baseline.
After CARDIAC surgery, PPCs were present in 10
(20%) of patients in the A group and 25 (50%) of patients
B group. Pneumonia occurred in 5 (10%) of patients in the
A group and in 7 (14%) of patients in the B (OR 95% CI).
Median days range 6–18 days in the B group. Finally,
postoperative patients compliance to respiratory therapy
was significantly improved.
Conclusion: Preoperative A strategy reduced the
incidence of PPCs an duration of postoperative hospital-
ization in patients at high risk of developing pulmonary
complication undergoing CARDIAC surgery. Also, post-
operative patient compliance to respirartory therapy
was significantly improved.
http://dx.doi:10.1016/j.jsha.2013.03.175
Current outcomes of the Glenn bidirectional cavo-
pulmonary connection for single ventricle
palliation
Waheed Raedi, Majid Al Fayyadh, Momdouh Al
Ahmadi, Bahaa Alsoufi
Objectives: The Glenn bidirectional cavopulmonary
connection (BCPC) is an established procedure in multi-
stage palliation of various single ventricle anomalies. We
aimed to report current outcomes following BCPC and to
examine risk factors affecting survival and progression to
next palliation stage.
Methods: 227 consecutive children with variable sin-
gle ventricle pathologies underwent BCPC from 2002 to
2007. Competing risks analyses were performed to model
events after BCPC (death and transition to Fontan) and
subsequently after Fontan (death and cardiac reopera-
tion); and to examine associated risk factors for poor
outcomes.
Results: There were 139 males (61%) with median age
of 7.6 months (interquartile range (IQR) 6.0–10.8) and med-
ian weight of 6.2 kg (IQR 5.2–7.4). Forty-three patients (19%)
had primary BCPC and 184 (81%) had prior palliation: aor-
topulmonary shunt (n = 83), Norwood (n = 55), pulmonary
artery band (n = 48), atrial septectomy (n = 25), pulmonary
artery reconstruction (n = 14), anomalous pulmonary
venous connection repair (n = 7), other (n = 8). Predomi-
nant ventricle was left morphology (n = 122, 54%), right
morphology (n = 95, 42%), two equally developed ventri-
cles (n = 10, 4%). Twenty-six patients (12%) had bilateral
SVC. Concomitant surgery included atrioventricular valve
repair (n = 18), pulmonary artery augmentation (n = 80),
percutaneous Fontan preparation (n = 34), other (n = 24).
Competing risks analysis showed that 5-years following
BCPC, approximately 17% have died, 76% have undergone
Fontan and 7% were alive awaiting or not qualifying for
Fontan. On multivariable analysis, risk factors for death
prior to Fontan were PVRI > 3 WU/M2 (HR 3.9, p = 0.001),
dominant right ventricle (HR 2.1, p = 0.03), prior palliation
other than aortopulmonary shunt (HR 0.4, p = 0.03). Com-
peting risks analysis showed that 3-years following 172
Fontan operations, approximately 10% have died, 6% have
undergone further cardiac surgery and 84% were alive and
free from reoperation. Overall, 8-year survival following
BCPC was only 74%.
Conclusions: Despite established selection criteria
and improved surgical technique and medical manage-
ment, there is a continuous failure and attrition risk fol-
lowing BCPC. Outcomes are influenced by underlying
cardiac anomaly; patients with dominant left ventricle
(i.e. tricuspid atresia, DILV) having the best survival
while those with dominant right ventricle (i.e. HLHS,
DORV with heterotaxy) having the worst survival.
Increased pulmonary vascular resistance remains a sig-
nificant factor affecting mortality.
http://dx.doi:10.1016/j.jsha.2013.03.176
Role of biomarkers to identify individuals with
silent cardiac disease to help improve primary
prevention
Yahia M. Elrakshy a, Akram M. Fayed b
aCardiology Department, Alexandria University Hospi-
tal, Egypt; bCritical Care Department, Faculty of Med-
icine, Alexandria, Egypt
Objectives: The aim of this study was to evaluate
power of identification of silent cardiac target organ dam-
age (TOD) in population receiving primary prevention
with the use of biomarkers.
Background: Primary prevention of cardiovascular
events could be improved by identifying patients with
silent cardiac TOD (i.e., myocardial ischemia, systolic
dysfunction, diastolic dysfunction, left ventricular hyper-
trophy or left atrial enlargement). Biomarkers used for
screening included high sensitive CRP [hs-CRP], high
sensitivity cardiac troponin T [hs-cTnT], or B-type natri-
uretic peptide [BNP].
Methods: The study included 271 asymptomatic
individuals already receiving primary prevention
A
BSTR
A
C
TS
170 ORAL AND POSTER ABSTRACTS J Saudi Heart Assoc
2013;25:113–172
therapy, they had their biomarkers evaluated. Identifica-
tion of silent cardiac TOD was done by transthoracic
echocardiography, stress echocardiography, and/or myo-
cardial perfusion imaging. Carotid–femoral pulse wave
velocity.
Results: Results showed that 96 (35%) patients had
evidence of cTOD. Left ventricular hypertrophy evalu-
ated by LV mass index showed the highest prevalence
(32.7%), followed by left ventricular diastolic dysfunction
(28.9%), left atrial enlargement (19.1%), systolic dysfunc-
tion (10.6%), ischemia (7.1%) and the lowest was PWV
(2.7%). The discrimination power as evaluated by area
under the curve [AUC] for BNP to identify any form of
silent cTOD was 0.79 overall and 0.83 in men, while for
hs-cTnT it was 0.70 and 0.74 in women. The combined
AUC for BNP and hs-cTnT together was 0.81 and 0.82
in men. Week discrimination power existed for of other
biomarkers, with AUCs of 0.61 for microalbuminuria,,
0.60 for hs-CRP, and 0.58 for eGFR.
Conclusions: Asymptomatic patients treated for pri-
mary prevention, existing silent cTOD could be identified
by BNP screening. The results of hs-cTnT was weaker
than that of BNP. Combining BNP plus hs-cTnT together
showed best results. Primary prevention could be
improved by Prescreening with BNP ± cTnT followed
by phenotyping.
http://dx.doi:10.1016/j.jsha.2013.03.177
Effect of circadian rhythm of blood pressure on
arterial wall stiffness and on left ventricular dia-
stolic dysfunction
Yahia M. Elrakshy, Akram M. Fayed, Mahmood M.
Hassanein
Background: Arterial stiffness is a risk factor for car-
diovascular morbidity and mortality. Variability of blood
pressure has been reported to be related to worse cardio-
vascular outcome. The relationship between the arterial
stiffness and the circadian rhythm of blood pressure (BP)
has been controversial. The objective was to the examine
impacts of BP variability on left ventricular diastolic func-
tion and arterial stiffness in the hypertensive patients.
Methods: Ambulatory BP monitoring, pulse wave
velocity, and echocardiography were performed in 268
patients (153 males, 47 ± 11 years) with HTN and
pre-HTN. BP was measured at the outpatient clinic and
24-h ABPM was performed. Using carotid femoral appla-
nation tonometry, PWA was performed for evaluation of
systemic arterial stiffness expressed as augmentation
index. Echocardiograms were performed and an average
of 3–6 cardiac cycles was done for all measurements
including the left ventricular mass index (LVMI), relative
wall thickness (RWT), trans mitral flow propagation
velocity (Vp), TDI, and midwall shortening fraction
(MWSF). Nocturnal dipping was defined as a reduction
of diastolic BP (DBP) by >10% of systolic BP (SBP) when
compared with the daytime values. Isolated systolic non-
dipping, is reduction of <10% in the SBP, When com-
pared with the daytime values. Isolated diastolic non-
dipping is reduction of <10% in the DBP. Both systolic
and diastolic non-dipping is reduction of <10% in both
SBP and DBP.
Results: Among groups, the clinic SBP and DBP,
daytime mean BP of 24-h ABPM, gender and body mass
index were not statistically different. Augmentation pres-
sure (AP), augmentation index (AI) showed statistically
significant difference (p = 0.008 and 0.021, respectively).
Multivariate analysis showed that isolated diastolic
non-dipping was correlated with arterial stiffness
expressed as AI only in young group.
http://dx.doi:10.1016/j.jsha.2013.03.178
Feasibility of using ivabridine in adult congenital
heart disease patients
Zakariya Albinmousa, Khalid Alnajashi,
Khalid Dagriri, Ahmed Alfagih, Saleh Alghamdi
Background: Beta Blockers have been the main
agent to control the heart rate in Fontan patients. Ivabri-
dine which is a selective SA node inhibitor has been used
in adult cardiac patient with successful result in control-
ling heart rate for those who did not respond to beta
blockers alone. This agent has not been reported to be
used in adult congenital heart disease patients.
Objective: To determine the feasibility of using iva-
bridine in patient with adult congenital heart disease and
inappropriate sinus tachycardia who failed to respond to
beta blockers.
Methods: 3 patients all with single ventricle physiol-
ogy were on maximum tolerable dose of Beta Blockers,
with inappropriate sinus tachycardia started on ivabri-
dine. Average follow up was 52 weeks with regular holter
monitor. Pro-BNP, 6 min walk test, and echocardiogra-
phy at baseline and 24 weeks of follow up. Physical exam-
ination and interrogation for any detected side effect was
done on each visit.
Result: At baseline the average heart rate was 100 ± 4
BPM, ivabridine started on with target dose 7.5 mg BD.
The mean average heart rate at 12 weeks was 83 BPM,
78 BPM on 24 weeks, and 85 BPM on 52 weeks. There
was no reported side effect by the patients or an effect
on single ventricle function.
Conclusion: ivabridine can be used in single ventri-
cle patients to reduce the heart rate in conjunction with
beta blockers. However larger study is needed to assess
its isolated long term effect on a diseased sinus node.
http://dx.doi:10.1016/j.jsha.2013.03.179
Identification of a novel homozygous NEXN gene
mutation in recessively inherited dilated
cardiomyopathy
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